Identification of Diosmin and Flavin Adenine Dinucleotide as Repurposing Treatments for Monkeypox Virus: A Computational Study

Int J Mol Sci. 2022 Sep 30;23(19):11570. doi: 10.3390/ijms231911570.

Abstract

The World Health Organization declared monkeypox a global public health emergency on 23 July 2022. This disease was caused by the monkeypox virus (MPXV), which was first identified in 1958 in Denmark. The MPXV is a member of the Poxviridae family, the Chordopoxvirinae subfamily, and the genus Orthopoxvirus, which share high similarities with the vaccinia virus (the virus used to produce the smallpox vaccine). For the initial stage of infection, the MPXV needs to attach to the human cell surface glycosaminoglycan (GAG) adhesion molecules using its E8 protein. However, up until now, neither a structure for the MPXV E8 protein nor a specific cure for the MPXV exists. This study aimed to search for small molecules that inhibit the MPXV E8 protein, using computational approaches. In this study, a high-quality three-dimensional structure of the MPXV E8 protein was retrieved by homology modeling using the AlphaFold deep learning server. Subsequent molecular docking and molecular dynamics simulations (MDs) for a cumulative duration of 2.1 microseconds revealed that ZINC003977803 (Diosmin) and ZINC008215434 (Flavin adenine dinucleotide-FAD) could be potential inhibitors against the E8 protein with the MM/GBSA binding free energies of -38.19 ± 9.69 and -35.59 ± 7.65 kcal·mol-1, respectively.

Keywords: E8 protein; MM/GBSA; dynamics simulation; homology modeling; molecular docking; monkeypox virus; repurposing treatment.

MeSH terms

  • Diosmin*
  • Flavin-Adenine Dinucleotide
  • Glycosaminoglycans
  • Humans
  • Molecular Docking Simulation
  • Monkeypox virus
  • Mpox (monkeypox)* / prevention & control
  • Smallpox Vaccine*
  • Viral Proteins

Substances

  • Glycosaminoglycans
  • Smallpox Vaccine
  • Viral Proteins
  • Flavin-Adenine Dinucleotide
  • Diosmin

Grants and funding

This research received no external funding.